malities in cardiac growth, contractility, and vascularity and represent the principle noninfectious cause of human morbidity and mortality. The inability of postnatal cardiac muscle cells to proliferate poses a major barrier to the functional restoration of the diseased heart. This has spawned intense interest-and equally intense controversy-regarding the therapeutic potential of cardiac stem cells. Regenerative stem cell therapies for heart disease necessitate an understanding of the molecular mechanisms that govern the fates, differentiation, and morphogenesis of the myriad cell types that comprise the heart and an ability to manipulate these mechanisms. Three new studies provide evidence for cardiac progenitor cells that have the potential to differentiate into all three of the major cell types of the heart: cardiac myocytes, smooth muscle cells, and endothelial cells (Kattman et al., 2006; Moretti et al., 2006; Wu et al., 2006) . These studies begin to address the plasticity and developmental potential of cardiac progenitor cells. At the same time, they raise interesting questions about the embryonic origins of cardiac cell lineages and the criteria used to define stem cells and their descendants. Here, we attempt to place these recent studies in perspective with the complex and often contentious conclusions in the field and to highlight important issues to be resolved in the future.
The Embryonic Origins of Cardiac Cell Lineages
Formation of the mature multichambered heart requires contributions of diverse cell types with specialized functions. Cardiac muscle cells become specialized to form ventricular and atrial myocytes, as well as cells of the conduction system. Smooth muscle cells form the venous and arterial vasculature, endothelial cells give rise to the endocardium and valves, and the epicardium serves as a source of precursors for the coronary vasculature.
Recent studies have demonstrated that the heart forms from two separate progenitor cell populations or "heart fields" that segregate from a common progenitor at gastrulation (Kelly et al., 2001; Cai et al., 2003; AbuIssa et al., 2004) . The earliest population of cardiac progenitors, referred to as the primary heart field, originates in the anterior splanchnic mesoderm and gives rise to the cardiac crescent, which ultimately contributes to the left ventricle and atria (Figure 1) . Cells from the cardiac crescent migrate medially and form the linear heart tube, which consists of an inner endocardial layer and an outer myocardial layer. Rightward looping and differential growth along the outer curvatures of the heart tube ultimately generates the multichambered heart (reviewed in Buckingham et al., 2005 ). An additional source of cardiac precursors, referred to as the secondary or anterior heart field, is derived from the pharyngeal mesoderm located medial to the cardiac crescent (Figure 1 ). Lineage tracing experiments have shown that the secondary heart field contributes primarily to the right ventricle and outflow tract (Kelly et al., 2001; Cai et al., 2003; Laugwitz et al., 2005) .
The primary and secondary heart fields can be distinguished by the expression of specific transcription factors and signaling molecules. The T-box transcription factor Tbx5 and the bHLH transcription factor Hand1, for example, mark the primary heart field, whereas Hand2, the LIM-homeodomain transcription factor Isl1, and Fgf10, among others, mark the secondary heart field (Kelly et al., 2001; Cai et al., 2003) . Mouse embryos with mutations in these and other genes display abnormalities in the corresponding regions of the heart (Buckingham et al., 2005) . Other cardiac regulatory genes, such as the homeobox gene Nkx2-5, are expressed in both heart fields and rely on different cis-regulatory elements for expression in these progenitor populations, demonstrating that the Formation of the heart requires the coordinated functions of cardiac myocytes, smooth muscle cells, endothelial cells, and connective tissue elements. Several recent studies now reveal that these different cell types arise from a common progenitor (Kattman et al., 2006; Moretti et al., 2006; Wu et al., 2006) . These findings raise interesting questions about the lineage relationships of cardiovascular progenitor cell populations and suggest possibilities for cardiac repair in both congenital and acquired heart disease.
transcriptional networks that drive cardiogenesis in different regions of the developing heart are distinct (reviewed in Schwartz and Olson, 1999) . Clonality, Self Renewal, and Multipotentiality Several studies, including recent papers in Cell and Developmental Cell, describe multipotent mesodermal progenitors that give rise to diverse cells types within the heart (Kattman et al., 2006; Moretti et al., 2006; Wu et al., 2006) . Before considering these results, it is worthwhile to consider the defining properties of stem cells: clonality, self renewal, and multipotentiality. Embryonic stem (ES) cells derived from the blastocyst represent the prototypic stem cell population capable of parenting the more than 200 somatic cell types. As development proceeds, stem cell progeny become progressively specialized and restricted in their developmental potential.
Lineage tracing with reporter genes is commonly used to demonstrate that a progenitor population can give rise to different cell types in the embryo. However, only a clonal analysis can show unequivocally that a single cell is capable of generating progeny of multiple lineages. There have been numerous recent claims regarding the existence of cardiac stem cells with remarkably different characteristics. Part of the confusion derives from the fact that, in many cases, the "stem cell" populations are almost certainly heterogeneous populations. The confounding and often contradictory properties of different cardiac stem cells raise questions about the criteria used to define them. These controversies illustrate the need for careful documentation of clonality, self renewal and the extent of multipotentiality in studies of cardiac stem cells.
Multipotent Cardiac Progenitors
Numerous studies have provided evidence for multipotent progenitor cells that give rise to the different cell types of the heart (Ema et al., 2006) . Such multipotentiality of muscle progenitor populations is emerging as a common theme, as demonstrated by the genesis of skeletal muscle and aortic smooth muscle cells from a common progenitor (Esner et al., 2006) .
Perhaps the best example of a multipotent progenitor is the hemangioblast-a mesodermal progenitor of hematopoietic and vascular lineages marked by the expression of brachyury (Bry) and the VEGF receptor Flk1. Evidence for the existence of hemangioblasts capable of parenting both endothelial and hematopoietic cells was recently obtained using a mouse ES cell/embryoid body differentiation assay (Huber et al., 2004 ) and a fate mapping strategy in the zebrafish (Vogeli et al., 2006) . Analysis of Flk1-lacZ knockin embryos has also revealed that Flk1 is expressed in progenitors with the potential to contribute to a broad range of mesodermal derivatives, including cells migrating from the primitive streak and progenitors located in the cardiac crescent, somites, and extraembryonic mesoderm (Ema et al., 2006) . Flk1 is indispensable for the formation of endothelial and hematopoietic lineages, but it is not absolutely required for the development of other mesodermal lineages such as the cardiac muscle lineage (Ema et al., 2006) .
It is particularly interesting that multipotent cardiovascular stem cells can also be isolated from the adult heart. Beltrami et al. (2003) have described Lin − /ckit + cells isolated from the adult rat heart that display the properties of stem cells and are able to give rise to cardiac myo- The heart forms from two heart fields. Scanning electron micrographs of representative stages of mouse development are shown with derivatives of the primary and secondary heart fields shown in color (left column; adapted from Kaufman, 1992) . The individual panels show the characteristics and lineage relationships of cardiac progenitor cells as described in Kattman et al. (2006) cytes, smooth muscle cells, and endothelial cells when cultured in vitro. Moreover, injection of these cells into the infarcted, ischemic heart improves myocardial function. Whether these cells represent remnants of embryonic cardiogenic precursors or a separate cell population remains to be determined. The observation that cardiospheres (spherical, cellular aggregates formed from a clonal cell population of unknown origin) can be isolated and exponentially expanded from adult human and mouse hearts further illustrates the proliferative and developmental potential of adult cardiac progenitors (Messina et al., 2004) . Using ES cells bearing a green fluorescent protein (GFP) reporter targeted to the Bry gene, Kattman et al. (2006) showed that a Flk1 − /GFP-Bry + progenitor can give rise sequentially, in culture, to two distinct populations of Flk1 + /GFP-Bry + progenitors. The first corresponds to the hemangioblast, which parents endothelial and hematopoietic lineages, and the second is capable of generating cardiac myocytes, vascular smooth muscle cells, and endothelial cells (Figure 1 ). The latter cell, which is the cardiovascular equivalent of the hemangioblast (referred to as a cardiovascular colony-forming cell), expresses Flk1 prior to cardiac markers, such as Nkx2-5, GATA4, and MEF2C. Cardiovascular colony-forming cells appear to be capable of generating both the primary and secondary heart fields, as shown by the nearly mutually exclusive expression of Tbx5 and Isl1, respectively, in clonal colonies. These findings are consistent with conclusions that the two heart fields develop from a common progenitor with endothelial potential and segregate early in development (Meilhac et al., 2004) .
Cardiovascular colony-forming cells could also be isolated from head-fold stage mouse embryos and clonally expanded in culture to generate colonies that expressed endothelial, vascular smooth muscle, and cardiac markers. This study, together with previous studies (Huber et al., 2004; Ema et al., 2006) , collectively support the hypothesis that Flk1 expression identifies multilineage mesodermal progenitors that can acquire a cardiac muscle fate. A future challenge will be to determine whether such Flk1 + progenitors are fully committed to cardiovascular lineages during embryogenesis or whether they possess broader developmental capacity following injury or when placed in a permissive environment.
Using transgenic mice bearing an enhanced yellow fluorescent protein (eYFP) reporter controlled by the Nkx2-5 enhancer as an early cardiac marker, we isolated cardiac progenitors from cardiac crescent, heart tube, and looped heart of mouse embryos by flow cytometry (Masino et al., 2004) . Transcriptome analysis revealed stage-specific molecular signatures of cardiac progenitors from each of these developmental periods (Masino et al., 2004) . Notably, cardiac progenitors isolated from the cardiac crescent were enriched in transcripts commonly expressed in cardiac, endothelial, and hematopoietic lineages (Masino et al., 2004) . Wu et al. (2006) used a similar approach to isolate cardiac progenitors from mouse embryos and differentiated ES cells expressing Nkx2-5-GFP. Nkx2-5-GFP + cells obtained from ES cultures displayed high proliferative capacity and were capable of generating clonal colonies with cardiac and smooth muscle phenotypes in vitro. These cells expressed modest levels of the stem cell markers ckit and Sca1 but did not express endothelial markers, suggesting that endothelial and myogenic lineages had already segregated by the time the Nkx2-5-GFP transgene was activated. Nkx2-5-GFP + cells isolated from hearts of E9.5 mouse embryos were also able to generate cardiac and smooth muscle lineages when allowed to differentiate en mass in vitro. Under these conditions, Nkx2-5-GFP expression segregated with cardiac markers, whereas smooth muscle markers were restricted to GFP − cells, suggesting that maintenance of Nkx2-5 expression characterizes the cardiac phenotype. Attempts to isolate and expand a clonal Nkx2-5-GFP + /ckit + cell population from the embryo were unsuccessful, as were efforts to direct Nkx2-5-GFP + /ckit + cells to other fates (i.e., neural, skeletal muscle, hematopoietic lineages), which leaves open the question of whether multipotentiality is unique to ESderived progenitors. Thus, Nkx2-5-GFP + /ckit + bipotential cardiovascular progenitors appear to be more restricted in developmental potential than the progenitors of cardiovascular colony-forming cells described by Kattman et al. (2006) . Consistent with this notion, the progenitors of cardiovascular-colony forming cells did not express Nkx2-5 or other cardiac markers, suggesting they exist earlier in a developmental pathway than the Nkx2-5-GFP + /ckit + progenitors (Kattman et al., 2006) .
Additional evidence for multipotent embryonic cardiac progenitors emerges from the studies of Laugwitz et al. (2005) and Moretti et al. (2006) , who showed by lineage tracing that Isl1 + cells, referred to as multipotent isl1 + cardiac progenitors (MICPs), contribute to endothelial, endocardial, smooth muscle, conduction system, right ventricular, and atrial myogenic lineages (Figure 1 ). Using flow cytometry, Isl1 expressing cells were isolated from the developing heart tube of E8.0-8.5 mouse embryos and, following expansion in a mesenchymal feeder layer system, were observed to spontaneously express endothelial, cardiac, and smooth muscle markers. ES cell-derived Isl1 + cardiac progenitors marked by expression of GFP from the Nkx2-5 locus were also able to give rise to more restricted progenitor cell populations that coexpressed Isl1 and Nkx2-5 (displaying cardiac and smooth muscle potential) or Isl1 and Flk1 (displaying endothelial potential). Moretti et al. (2006) liken the multipotent isl1 + cardiac progenitor to the hematopoietic stem cell, which is able to reconstitute all blood cell lineages in vivo. Although this is an interesting analogy, the inability, thus far, to clonally generate the full spectrum of cardiac cells from a single Isl1 + progenitor in vivo, the restriction of Isl1 expression to the secondary heart field, and the existence of numerous other progenitor populations that contribute to the heart, suggest that heart development is not so simple.
Outstanding Questions
The realization that diverse cell types of the heart can arise from common progenitors raises numerous questions for the future. For example, what dictates the decision of cardiovascular progenitors to adopt one fate versus another? Bone morphogenetic proteins (BMPs) and Wnts play positive and negative roles in specification of cardiac cell fates. How these and other signals impinge on the transcriptional machinery that directs cardiac muscle, smooth muscle, and endothelial cell fates remains to be determined. The relative contributions of various progenitor populations (e.g., primary and secondary heart fields, epicardium, etc.) to the diverse cell types of the heart also remain to be resolved.
Why do the cardiac progenitors described by different groups display different characteristics, and what are the relationships between different multipotent cardiac progenitors? Given that the path from a progenitor to a fully differentiated cell type, be it cardiac myocyte, smooth muscle, or endothelial, represents a continuum of development, it is likely that numerous variables, such as the developmental time of isolation, the anatomical source of cells, as well as culture conditions affect the phenotypes of cells along the pathway. In addition, different markers used for isolation and identification of progenitor cells undoubtedly select for specific subsets of cells. Cardiac progenitors isolated from the adult heart also display distinct and overlapping traits based on their multilineage diversification, cell surface markers, proliferative capacity, and location within the heart (Beltrami et al., 2003; Oh et al., 2003; Martin et al., 2004) . Limited knowledge exists regarding the relationships of these progenitors to one another or the molecular networks that regulate their proliferation, self renewal, or lineage differentiation states. Studies of isolated stem cells that use ex vivo marker expression data to define plasticity and fate potential of putative cardiac progenitors tell us what is possible in a tissue culture dish but not necessarily what actually happens in vivo during development and disease. This issue is especially relevant to studies in which putative stem cells are being used in humans to treat myocardial disease. There is clearly room for strengthening the link between basic science and clinical studies.
The propensity of ES-derived cells to generate teratomas in vivo limits their use in human regenerative therapies. Multipotent cardiac progenitors, therefore, represent a potentially attractive alternative for cardiac repair. Clinical trials are already underway using hematopoietic and mesenchymal stem cells for restoration of function in the infarcted and failing heart, and initial successes have been touted. Nevertheless, numerous hurdles remain, and caution is warranted. The timing of cell delivery following injury, the identity and number of cells delivered, the mode of delivery and the long-term benefits are issues that remain to be addressed. Moreover, it is unclear whether cell-based therapies could limit the progression of heart failure or whether autologous stem cell populations are capable of transdifferentiating to a cardiac fate and repopulating the injured human heart. Further analysis of embryonic as well as adult cardiac progenitors with respect to their derivation, molecular regulation, and relationships to one another promises to enhance our understanding of cardiac development and disease and may serve as a platform for developing therapies to treat congenital and acquired heart disease.
